Author

S. K. Anand

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. D. Davidson· 1 shared A. F. Lingappa· 1 shared A. Kerelsky· 1 shared A. Macieik· 1 shared A. Mueller-Schiffmann· 1 shared A. P. Possemato· 1 shared A. R. Moreira· 1 shared A. T. Harding· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. D. Davidson

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CD14 Blockade Does Not Improve Outcomes of Deep Vein Thrombosis Following Inferior Vena Cava Stenosis in Mice

N. Pandey, H. Kaur, L. Chandaluri, S. K. Anand, H. Chokhawala, T. Magdy, K. Stokes, A. W. Orr, O. Rom, N. Dhanesha

This study investigates whether CD14 blockade improves DVT outcomes after IVC stenosis in mice, finding no significant effect on thrombus weight, incidence, or neutrophil recruitment.

bioRxiv · Jan 10, 2024 · PreprintPathology

A Pan-respiratory Antiviral Chemotype Targeting a Host Multiprotein Complex

M. Michon, A. Mueller-Schiffmann, A. F. Lingappa, S. F. Yu, L. Du, F. Deiter, S. Mallesh, J. Crabtree, U. F. Lingappa, A. Macieik, L. Mueller, P. N. Ostermann, M. Andree, O. Adams, H. Schaal, , K

The paper identifies a novel antiviral chemotype effective against multiple respiratory viruses by targeting a host multi-protein complex involved in viral lifecycle and innate immunity.

bioRxiv · Jan 17, 2021Biochemistry

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

T. M. Yaron, B. E. Heaton, T. M. Levy, J. L. Johnson, T. X. Jordan, B. M. Cohen, A. Kerelsky, T.-Y. Lin, K. M. Liberatore, D. K. Bulaon, E. R. Kastenhuber, M. N. Mercadante, K. Shobana-Ganesh, L. He, R. E. Schwartz, , M Kavanagh-Williamson

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

bioRxiv · Aug 14, 2020 · PreprintMicrobiology